THE SAVER TRIAL: STATINS FOR VENOUS EVENT REDUCTION IN PATIENTS WITH VENOUS THROMBOEMBOLISM
- Registry ID
- CTO 2095
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- OTTAWA HOSPITAL RESEARCH INSTITUTE
- Start date
- 2021-06-14
- Last update
- 2020-07-28
Conditions
Related clinical trials
- THE PARTUM (POSTPARTUM ASPIRIN TO REDUCE THROMBOEMBOLISM UNDUE
MORBIDITY) TRIAL
- A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL STUDY OF REGN9933, A FACTOR XI MONOCLONAL ANTIBODY, FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ELECTIVE, UNILATERAL, TOTAL KNEE ARTHROPLASTY
- A MULTICENTER, RANDOMIZED, OPEN-LABEL, BLINDED ENDPOINT EVALUATION, PHASE 3 STUDY COMPARING THE EFFECT OF ABELACIMAB RELATIVE TO APIXABAN ON VENOUS PIXABAN ON VENOUS THROMBOEMBOLISM (VTE) RECURRENCE AND BLEEDING IN PATIENTS WITH CANCER ASSOCIATED VTE (ASTER)
- PRIMARY THROMBOPROPHYLAXIS IN PATIENTS WITH MALIGNANCY AND CENTRAL VENOUS CATHETERS: A RANDOMIZED CONTROLLED TRIAL (TRIM-LINE)
- A PILOT STUDY ASSESSING THE FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL EVALUATING ASPIRIN IN POSTPARTUM WOMEN AT RISK OF DEVELOPING VENOUS THROMBOEMBOLISM.
- LOW-MOLECULAR-WEIGHT HEPARIN TO PREVENT RECURRENT VTE IN PREGNANCY: A RANDOMIZED CONTROLLED TRIAL OF TWO DOSES
View on source registry